Randomized double blind trial of prednisolone and azathioprine, vs. prednisolone and placebo, in the treatment of pemphigus vulgaris

Journal of the European Academy of Dermatology and Venereology

Volumn 27, Issue 10, 2013, Pages 1285-1292

  Chams Davatchi, C ^a   Mortazavizadeh, A ^a   Daneshpazhooh, M ^a   Davatchi, F ^b   Balighi, K ^a   Esmaili, N ^a   Akhyani, M ^a   Hallaji, Z ^a   Seirafi, H ^a   Mortazavi, H ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; PLACEBO; PREDNISOLONE;

ADULT; AGE; ARTICLE; BLISTER; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG WITHDRAWAL; EROSION; FACE; FEMALE; GENDER; HEALING; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTENTION TO TREAT ANALYSIS; LIMB; MAJOR CLINICAL STUDY; MALE; MOUTH CAVITY; NECK; PEMPHIGUS VULGARIS; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SCALP; SKIN ULCER; STEROID THERAPY; TREATMENT OUTCOME; TRUNK;

ADULT; AZATHIOPRINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDPOINT DETERMINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PEMPHIGUS; PREDNISOLONE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84884905264     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2012.04717.x     Document Type: Article

References (22)

1. Joly P, Sin C,. Pemphigus: a review. Ann Dermatol Venereol 2011; 138: 182-200.
2. Martin LK, Werth VP, Villaneuva EV, Murrell DF,. A systematic review of randomized controlled trials for pemphigus vulgaris and pemphigus foliaceus. J Am Acad Dermatol 2011; 64: 903-908.
3. Frew JW, Martin LK, Murrell DF,. Evidence-based treatments in pemphigus vulgaris and pemphigus foliaceus. Dermatol Clin 2011; 29: 599-606.
4. Schmidt E, Goebeler M, Zillikens D,. Rituximab in severe pemphigus. Ann N Y Acad Sci 2009; 1173: 683-691.
5. Chams-Davatchi C,. Prevalence and treatment of pemphigus in Iran. Dermatol Clin 2011; 29: 681-683.
6. Lolis M, Toosi S, Czernik A, Bystryn JC,. Effect of intravenous immunoglobulin with or without cytotoxic drugs on pemphigus intercellular antibodies. J Am Acad Dermatol 2011; 64: 484-489.
7. Gürcan HM, Jeph S, Ahmed AR,. Intravenous immunoglobulin therapy in autoimmune mucocutaneous blistering diseases: a review of the evidence for its efficacy and safety. Am J Clin Dermatol 2010; 11: 315-326.
8. Amagai M, Ikeda S, Shimizu H, et al. A randomized double-blind trial of intravenous immunoglobulin for pemphigus. J Am Acad Dermatol 2009; 60: 595-603.
9. Schmidt E, Zillikens D,. Immunoadsorption in dermatology. Arch Dermatol Res 2010; 302: 241-253.
10. Firooz A, Ghandi N, Hallaji Z, Chams-Davatchi C, Valikhani M, Karbakhsh Davari M,. Role of thiopurine methyltransferase activity in the safety and efficacy of azathioprine in the treatment of pemphigus vulgaris. Arch Dermatol 2008; 144: 1143-1147.
11. Murrell DF, Dick S, Ahmed AR, et al. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. J Am Acad Dermatol 2008; 58: 1043-1046.
12. Shahshahani MM, Azizahari S, Soori T, et al. Hepatotoxicity and liver enzyme alteration in patients with immunobullous diseases receiving immunosuppressive therapy. J Dermatol 2011; 38: 1153-1157.
13. Mimouni D, Nousari CH, Cummins DL, Kouba DJ, David M, Anhalt GJ,. Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris. J Am Acad Dermatol 2003; 49: 1059-1062.
14. Samadi Z, Gorouhi F, Davari P, Firooz A,. Think globally, act locally: expert opinions from Asia on the diagnosis and treatment of pemphigus vulgaris. Indian J Med Sci 2007; 61: 144-151.
15. Burton JL, Greaves MW,. Azathioprine and pemphigus vulgaris. Arch Dermatol 1973; 108: 424.
16. Aberer W, Wolff-Schreiner EC, Stingl G, Wolff K,. Azathioprine in the treatment of pemphigus vulgaris. A long-term follow-up. J Am Acad Dermatol 1987; 16: 527-533.
17. Chams-Davatchi C, Esmaili N, Daneshpazhooh M, et al. Randomized controlled open-label trial of four treatment regimens for pemphigus vulgaris. J Am Acad Dermatol 2007; 57: 622-628.
18. Beissert SSS, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of pemphigus. Arch Dermatol 2006; 142: 1447-1454.
19. Benoit Corven C, Carvalho P, Prost C, et al. Treatment of pemphigus vulgaris by azathioprine and low doses of prednisone (Lever scheme)]. Ann Dermatol Venereol 2003; 130: 13-15.
20. Chaidemenos GCh, Mourellou O, Koussidou T, Tsatsou F,. An alternate-day corticosteroid regimen for pemphigus vulgaris. A 13-year prospective study. J Eur Acad Dermatol Venereol 2007; 21: 1386-1391.
21. Chaidemenos G, Apalla Z, Koussidou T, Papagarifallou I, Ioannides D,. High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi-centre, comparative study. J Eur Acad Dermatol Venereol 2011; 25: 206-210.
22. Beissert S, Mimouni D, Kanwar AJ, Solomons N, Kalia V, Anhalt GJ,. Treating Pemphigus vulgaris with prednisolone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial. J Invest Dermatol 2010; 130: 2041-2088.